Precedex Special Investigation (in Pediatric Patients)

CompletedOBSERVATIONAL
Enrollment

111

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

August 8, 2022

Study Completion Date

August 8, 2022

Conditions
Sedation
Interventions
DRUG

Dexmedetomidine Hydrochloride

"\[Sedation during and after mechanical ventilation in the intensive care setting\] For pediatric patients ages of 6 years and over, dexmedetomidine is usually administrated by continuous intravenous (IV) infusion of at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.0 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition.~For pediatric patients with corrected gestational ages (gestational age + postnatal age) of 45 weeks to under 6 years, dexmedetomidine is usually administrated by continuous IV infusion at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.4 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition. The dosing rate could be decreased according to the patient's condition as appropriate."

Trial Locations (1)

Unknown

Pfizer Japan Local Country Office, Tokyo

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Maruishi Pharmaceutical

INDUSTRY

lead

Pfizer

INDUSTRY

NCT04040439 - Precedex Special Investigation (in Pediatric Patients) | Biotech Hunter | Biotech Hunter